<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00284128</url>
  </required_header>
  <id_info>
    <org_study_id>DFI6032</org_study_id>
    <nct_id>NCT00284128</nct_id>
  </id_info>
  <brief_title>AVE7688 in Patients With Mild to Moderate Blood Pressure</brief_title>
  <acronym>RAVEL-1</acronym>
  <official_title>Double-blind, Randomized, Parallel-group, Dose Ranging, Multicenter Study to Evaluate the Efficacy and Safety of 2.5, 10, 35 and 50 mg AVE 7688 Once Daily, Using 100 mg Losartan-potassium Once Daily as Calibrator, for 12 Months Treatment, in Patients With Mild to Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the antihypertensive efficacy of 4 different AVE 7688
      doses on the change from baseline in trough diastolic blood pressure at the end of week 12.

      The secondary objectives are:

        -  To assess the antihypertensive efficacy of 4 different AVE 7688 doses on the change from
           baseline in trough systolic blood pressure at the end of week 12

        -  To compare the percentages of responders after 12 week of treatment

        -  To evaluate the long term safety and tolerability of AVE 7688 with particular attention
           to angioedema
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective multi-center, randomized, double-blind, active-controlled
      parallel-group, dose ranging study with 5 treatment groups (AVE7688 at 4 different dosages,
      and losartan-potassium 100 mg). There will be 3 study phases: placebo lead-in, treatment, and
      follow-up.

      During the placebo lead-in phase (duration 3 to 4 weeks), patients will discontinue
      concomitant treatment with any antihypertensive or vasodilating agents and will receive
      single-blind placebo until randomization. Patients who meet the inclusion and exclusion
      criteria will be randomized to receive once-daily oral doses of either 2.5, 10, 35 or 50 mg
      AVE7688, or 100 mg losartan-potassium.

      The treatment phase will consist of two parts: an efficacy evaluation period, with a 2 week
      titration period (from randomization to week 2, visit T1 to visit T3) up to 12 weeks,
      followed by a long-term safety evaluation period until the end of week 52. Antihypertensive
      treatment such as diuretics, beta blockers or calcium channel blockers can be introduced or
      re-introduced if indicated during the long term safety evaluation period but angiotensin
      converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBs) are not
      permitted.

      An additional visit (visit F1) will occur two weeks after the last dose of study medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in trough diastolic blood pressure at the end of week 12.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in trough systolic blood pressure at the end of week 12, percentages of responders after 12 week of treatment.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of long term safety and tolerability of AVE7688 with particular attention to angioedema.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1940</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>ilepatril (2.5 mg ) once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVE7688 oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ilepatril (10 mg) once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVE7688 oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ilepatril (35 mg) once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVE7688 oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ilepatril (50 mg) once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVE7688 oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan-potassium (100 mg) once daily</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVE7688</intervention_name>
    <description>oral administration (capsules)</description>
    <arm_group_label>ilepatril (2.5 mg ) once daily</arm_group_label>
    <arm_group_label>ilepatril (10 mg) once daily</arm_group_label>
    <arm_group_label>ilepatril (35 mg) once daily</arm_group_label>
    <arm_group_label>ilepatril (50 mg) once daily</arm_group_label>
    <other_name>ilepatril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan-potassium</intervention_name>
    <description>oral administration (capsules)</description>
    <arm_group_label>Losartan-potassium (100 mg) once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mild-to-moderate, treated or untreated, essential hypertension, as
             defined by the JNC VII (Joint National Committee on the Prevention, Detection,
             Evaluation, and

        Treatment of High Blood Pressure, Seventh report ) guidelines who meet the following BP
        eligibility criteria:

          -  mean SeSBP (Seated systolic blood pressure) ≥140 mm Hg and &lt;180 mm Hg and mean SeDBP
             (Seated diastolic blood pressure) ≥90 mm Hg and &lt;110 mm Hg at two consecutive
             qualifying visits in the placebo lead-in phase

          -  variability between the mean BP measurements on the 2 consecutive qualifying visits is
             less or equal 7 mm Hg for SeDBP.

        Exclusion Criteria:

          -  Refusal or inability to give informed consent

          -  Patients who have previously been treated with AVE7688

          -  Patients who cannot stop their anti-hypertensive treatment

          -  Known history of secondary hypertension, including patients with endocrine disorders
             such as pheochromocytoma, active hyperthyroidism, or untreated hypothyroidism

          -  Severe hypertension

          -  Women of child bearing potential, who have a positive serum pregnancy test, or who do
             not agree to use an accepted method of contraception

          -  Women who are breast feeding

          -  Patients with non-cardiac progressive fatal disease

          -  Patients with immunological or hematological disorders

          -  Requirement for concomitant treatment that could bias the primary evaluation

          -  Unstable insulin-dependent diabetes mellitus

          -  History of stroke, intracranial hemorrhage or transitory ischemic attack within the
             previous year

          -  Likelihood of poor compliance both with treatment and study design

          -  Patient is the investigator, sub-investigator, research assistant, pharmacist, study
             coordinator, or other staff member or relative there of directly involved in the
             conduct of the study

          -  Administration of any investigational drug within the preceding 30 days

          -  Abuse of drugs or alcoholic beverages within 1 year prior to the start of the study

          -  Patients taking herbal or dietary compounds that have the potential to influence blood
             pressure

          -  Contraindications to losartan-potassium as per local package insert

          -  History of hypersensitivity or angioedema with ACE inhibitors or NEP inhibitors,
             patients with hereditary or idiopathic angioedema, patients with allergic reaction in
             which urticaria or angioedema was the manifestation

          -  Impaired hepatic function

          -  Known unilateral or bilateral renal artery stenosis

          -  Serum potassium &gt; 5.5 mmol/L

          -  Impaired renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Causeway Bay</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2006</study_first_submitted>
  <study_first_submitted_qc>January 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2006</study_first_posted>
  <disposition_first_submitted>April 19, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 19, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 18, 2016</disposition_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular Disease C14</keyword>
  <keyword>vascular disease C14.907</keyword>
  <keyword>hypertension C14.907.489</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

